Tirzepatide 10mg

What Is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide and the first dual GIP and GLP-1 receptor co-agonist to be characterised in metabolic research. Also referenced by the research alias GLP2-T, it is studied for its effects on glucose regulation, appetite signalling and body-weight endpoints. This listing is for a lyophilised research-grade vial supplied for laboratory and research use only.

How Tirzepatide Works

Unlike single-pathway GLP-1 agonists, tirzepatide activates two incretin receptors at once — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. In published pharmacology it behaves as an “imbalanced” agonist: potency at the GIP receptor is close to that of native GIP, while its GLP-1 receptor activity is comparatively weaker and biased toward cAMP signalling. A C20 fatty-diacid moiety promotes albumin binding, which is what extends its circulating half-life. Together these pathways are associated in study models with improved insulin sensitivity, glucagon suppression and reduced food intake.

Product Details & Specifications

• Compound: Tirzepatide (research alias GLP2-T)
• Presentation: 10 mg lyophilised powder, single sealed vial
• Sequence: 39-amino-acid peptide with C20 fatty-diacid side chain
• Form: white lyophilised cake, reconstituted before use
• Intended use: in-vitro / laboratory research only — not for human or veterinary use

Half-Life & Frequency

Tirzepatide has an approximate 120-hour (~5-day) half-life, driven by its albumin-binding fatty-diacid tail. In clinical study protocols this long half-life supported once-weekly administration. The extended exposure profile is one of the properties that distinguishes it from shorter-acting peptides in the same class.

Reconstitution & Storage (Research Handling)

Lyophilised tirzepatide is stable for extended periods when kept cold: roughly 24+ months at −20°C and 12–24 months at 2–8°C. For reconstitution, laboratories typically use bacteriostatic water (0.9% benzyl alcohol), which preserves the solution for multi-draw research over about 28 days when refrigerated at 2–8°C. Best practice noted in the literature: let a cold vial reach room temperature for 15–30 minutes before opening to avoid condensation, add diluent slowly against the vial wall rather than directly onto the powder, and do not freeze a reconstituted vial — freeze-thaw cycles degrade the peptide chain and reduce potency.

Dosing in Clinical Studies

The information below describes published clinical-trial protocols and is provided for research context only — it is not a dosing recommendation. In the SURPASS and SURMOUNT programmes, administration began at 2.5 mg weekly and was escalated by 2.5 mg roughly every four weeks toward maintenance doses of up to 15 mg weekly. Slow titration was the single most effective strategy for limiting gastrointestinal side effects during dose escalation.

Reported Side Effects

In clinical research, tirzepatide’s most frequently reported adverse events were gastrointestinal — nausea, diarrhoea, vomiting and constipation. Nausea was reported by roughly 24% of participants across the 5–15 mg doses versus about 9.5% on placebo. The majority of events were mild to moderate, occurred most often during the first weeks of dose escalation, and declined over time at each maintenance dose. These are research observations, not a safety profile for any non-clinical use.

Tirzepatide vs Semaglutide vs Retatrutide

The three most-studied incretin peptides differ by the number of receptors they target:

• Semaglutide — single GLP-1 agonist; ~15% mean weight loss at 2.4 mg in trial data.
• Tirzepatide — dual GIP + GLP-1 agonist; ~21% mean weight loss at 15 mg (SURMOUNT-1, 72 weeks).
• Retatrutide — triple GIP + GLP-1 + glucagon agonist; ~28% mean weight loss at 12 mg, but still investigational with no expected approval before ~2027.

For research comparisons within the same class, see Retatrutide 10mg and the higher-capacity Retatrutide 40mg Pen & Kit. Peptides studied for different endpoints include the recovery-focused BPC-157 & TB-500 blend, IGF-1 LR3 1mg, and HCG 5000 IU.

Where to Buy Tirzepatide Online

KGEAR U.S supplies research-grade tirzepatide with discreet, tracked shipping and crypto checkout. Browse the full peptides collection for related GLP-1, recovery and metabolic research peptides, including Melanotan-II (MT-2). All compounds are sold strictly for research use only.

Frequently Asked Questions

Is tirzepatide the same as Mounjaro or Zepbound?

Tirzepatide is the peptide compound studied in those clinical programmes. This listing is a research-grade lyophilised vial supplied for laboratory use, not a branded pharmaceutical product.

What purity is this tirzepatide?

How is it a “dual agonist”?

It activates both the GIP and GLP-1 receptors, whereas semaglutide activates only GLP-1. See the comparison section above.

What is the half-life?

Approximately 120 hours (~5 days), which in clinical studies supported once-weekly dosing.

How should lyophilised tirzepatide be stored?

Cold and dry before reconstitution (−20°C for long-term, 2–8°C shorter-term). After reconstitution with bacteriostatic water, refrigerate at 2–8°C and do not freeze.

How does it compare to retatrutide?

Retatrutide is a triple agonist with higher weight-loss figures in early trials but remains investigational; tirzepatide is the more extensively studied dual agonist.

Is this for human use?

No. All products are supplied strictly for laboratory and research use only, not for human or veterinary consumption.

Disclaimer

This product is sold for laboratory and research use only. It is not a drug, food or supplement, and is not intended to diagnose, treat, cure or prevent any disease, nor for human or animal consumption. All efficacy, mechanism and dosing information above is a summary of published clinical research provided for scientific context only and is not medical advice. Handling of research compounds is the sole responsibility of the qualified purchaser.